Related Experiment Video
Updated: Jun 10, 2026

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
Quantitative studies of the metabolism of furazolidone by rat liver microsomes
L H Vroomen1, B van Ommen, P J van Bladeren
1State Institute for Quality Control of Agricultural Products, Toxicology Section, Bornsesteeg 45, 6708 PD Wageningen, The Netherlands.
Abstract:
The nitrofuran, furazolidone, is metabolized by rat liver microsomes under both aerobic and anaerobic conditions, the rates for microsomes from 3-methylcholanthrene-induced male rats being 3.52 and 4.26 nmol/mg protein/min, respectively. The two major metabolites formed are the well-known 3-(4-cyano-2-oxobutylideneamino)-2-oxazolidone, and 2,3-dihydro-3-cyanomethyl-2-hydroxy-5-nitro-1alpha,2-di-(2-oxo-oxazolidin-3-yl)iminomethylfuro[2,3-b]furan (accounting for 16.6 and 16.4% of total extractable radioactivity, respectively). Cytochrome P-450 is not involved in the conversion of furazolidone, which was converted by rat liver microsomes to products identical to those obtained upon incubation with purified NADPH-cytochrome P-450 reductase, which is a microsomal reductase. During metabolism, a considerable amount of material (2-3% of total metabolites) became covalently bound to microsomal protein. This covalent binding could be inhibited by addition of glutathione, which also resulted in an almost complete shift from non-polar to water-soluble metabolites. No interaction of furazolidone with added calf thymus DNA was detected.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Measurement of Bioavailability: Pharmacokinetic Methods
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

